Redhawk Wealth Advisors Inc. Has $2.15 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Redhawk Wealth Advisors Inc. lifted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,339 shares of the pharmaceutical company’s stock after purchasing an additional 153 shares during the quarter. Redhawk Wealth Advisors Inc.’s holdings in Vertex Pharmaceuticals were worth $2,150,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in VRTX. Edgewood Management LLC raised its holdings in Vertex Pharmaceuticals by 7,876.3% during the third quarter. Edgewood Management LLC now owns 1,546,370 shares of the pharmaceutical company’s stock worth $719,186,000 after buying an additional 1,526,983 shares during the last quarter. Jennison Associates LLC increased its position in shares of Vertex Pharmaceuticals by 18.1% during the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock worth $2,581,373,000 after acquiring an additional 851,054 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Vertex Pharmaceuticals by 17.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock worth $2,231,858,000 after acquiring an additional 704,421 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Vertex Pharmaceuticals by 169.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 839,672 shares of the pharmaceutical company’s stock valued at $338,136,000 after acquiring an additional 528,029 shares in the last quarter. Finally, International Assets Investment Management LLC boosted its stake in Vertex Pharmaceuticals by 74,015.5% during the 3rd quarter. International Assets Investment Management LLC now owns 324,626 shares of the pharmaceutical company’s stock valued at $150,977,000 after purchasing an additional 324,188 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on VRTX. Royal Bank of Canada increased their price objective on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. StockNews.com cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. Morgan Stanley upped their target price on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Wells Fargo & Company dropped their price target on shares of Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Finally, William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Monday. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $490.38.

Vertex Pharmaceuticals Price Performance

VRTX opened at $424.26 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a fifty day moving average price of $445.93 and a 200-day moving average price of $467.13.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. During the same period in the previous year, the business earned $3.67 earnings per share. The firm’s revenue was up 11.6% on a year-over-year basis. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.